A study of enhanced management in patients with treatment-resistant schizophrenia

Journal of Psychopharmacology

Volumn 11, Issue 4, 1997, Pages 349-356

  Mercer, Gavin ^a   Finlayson, Alan ^a   Johnstone, Eve C ^a   Murray, Claire ^a   Owens, David G C ^a  

^a ROYAL EDINBURGH HOSPITAL   (United Kingdom)

Author keywords

Intensive management; Risperidone; Social function; Symptomatic change; Treatment resistant schizophrenia

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; FEMALE; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0030834624     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100411     Document Type: Article

References (27)

1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R). American Psychiatric Association, Washington DC
2. Borison R L, Pathiraja A P, Diamond B I, Meibach R C (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmac Bull 28: 213-218
3. Chouinard G, Jones B, Remington G, Bloom D, Addington D, McEwan G W, Labelle A, Beuclair L, Arnott W (1993) A Canadian multi-centre placebo-controlled study of fixed doses of risperidonc and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmac 13: 25-40
4. Davis J M (1976) Recent developments in the drug treatment of schizophrenia. Am J Psychiat 133: 208-214
5. Dencker S J, May P R A (1988) From chronic mental hospital care to integration into society. In Dencker S J, Kulhanek F (eds), Treatment resistance in schizophrenia. Vieweg, Braunschweig, pp. 13-21
6. Feighner J P, Robins E, Guze S, Woodruff R A Jnr, Winokur G, Munoz R (1972) Diagnostic criteria for use in psychiatric research. Archs Gen Psychiat 26: 57-62
7. Foster P (1989) Neuroleptic equivalence. Pharmaceut J 243: 431-432
8. Guy W (1976) Abnormal involuntary movements scale (AIMS). In ECDU assessment manual. Department of Health Education and Welfare, Rockville, MD
9. Jablensky A, Schwaltz R, Tomov T (1980) WHO collaborative study on impairments and disabilities associated with schizophrenic disorders. A preliminary communication: objectives and methods. Acta Psychiat Scand 62 (Suppl. 285): 152-163
10. Johnstone E C (1989) Treatment resistant schizophrenia. Lancet 1: 431
11. Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double blind comparison versus chlorpromazine/benztropine. Archs Gen Psychiat 45: 789-796
12. Kane J M, McGlashan T H (1995) Treatment of schizophrenia. Lancet 346: 820-825
13. Kay S R, Fiszbein A, Opler L A (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13/2: 261-276
14. Liberman R P (1982) Assessment of social skills. Schizophr Bull 8: 63-83
15. Lingjaerde O, Ahlfors U G, Bech P, Dencker S J, Elgen K (1987) The UKU side effect rating scale. Acta Psychiat Scand 76 (Suppl. 334)
16. Macmillan J F, Crow T J, Johnson A L, Johnstone E C (1986) The Northwick Park study of first episodes of schizophrenia. III: Short term outcome in trial entrants and trial eligible patients. Br J Psychiat 148: 128-133
17. Marder S R, Meibach R C (1994) Risperidone in the treatment of schizophrenia. Am J Psychiat 151: 825-835
18. May P R A, Dencker S J, Hubbard J W, Midha K K, Liberman R P (1988) A systematic approach to treatment resistance in schizophrenic disorders. In Dencker S J, Kulhanek F (eds), Treatment resistance in schizophrenia. Vieweg, Braunschweig
19. Morrison R L, Bellack A S (1987) Social functioning of schizophrenic patients: clinical and research issues. Schizophr Bull 13: 715-725
20. National Institute of Mental Health (1964) Psychopharmacology Service Center, Collaborative Study Group. Phenothiazine treatment in acute schizophrenia: effectiveness. Archs Gen Psychiat 10: 246-261
21. Owens D G C (1996) Adverse effects of antipsychotic agents - do newer agents offer advantages? Drugs 51: 895-930
22. Owens D G C, Finlayson A, Mercer G, Johnstone E C (1997) The use of videotaped assessment in relation to a study of enhanced management in treatment-resistant schizophrenia. J Psychopharmac 11: 357-360
23. Peuskens J on behalf of the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiat 166: 712-726
24. Schulz P, Rey M-J, Dick P, Tissot R (1989) Guidelines for the dosage of neuroleptics II: Changing from daily oral to long acting injectable neuroleptics. Int Clin Psychopharmac 4: 105-114
25. Simpson G W, Levinson D F (1988) Can we increase the response to somatic therapies for schizophrenia? In Dencker S J, Kulhanek F (eds), Treatment resistance in schizophrenia. Vieweg, Braunschweig
26. Tuma A H, May P R A (1979) And if that doesn't work, what next? A study of treatment failures in schizophrenia. J Nerv Ment Dis 167: 566-571
27. Wojcik J D, Gelenberg A J, Labrie R A, Mieske M (1980) Prevalence of tardive dyskinesia in an outpatient population. Comp Psychiat 21: 370-380